Bio-Connect

Anti-TrkA+B+C Antibody [JJ084-04]

ET1701-16
HUABIO
ApplicationsImmunoFluorescence, Western Blot, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
Product group Antibodies
ReactivityHuman, Mouse, Rat
TargetNTRK1
100 ul
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    HUABIO
  • Product Name
    Anti-TrkA+B+C Antibody [JJ084-04]
  • Delivery Days Customer
    7
  • Applications
    ImmunoFluorescence, Western Blot, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
  • Applications Supplier
    WB,IF-Cell,IHC-P
  • Certification
    Research Use Only
  • Clonality
    Monoclonal
  • Clone ID
    JJ084-04
  • Concentration
    1 mg/ml
  • Conjugate
    Unconjugated
  • Gene ID4914
  • Target name
    NTRK1
  • Target description
    neurotrophic receptor tyrosine kinase 1
  • Target synonyms
    MTC, TRK, TRK1, TRKA, Trk-A, p140-TrkA, high affinity nerve growth factor receptor, Oncogene TRK, TRK1-transforming tyrosine kinase protein, gp140trk, neurotrophic tyrosine kinase, receptor, type 1, tropomyosin receptor kinase A, tropomyosin-related kinase A, tyrosine kinase receptor A
  • Host
    Rabbit
  • Isotype
    IgG
  • Protein IDP04629
  • Protein Name
    High affinity nerve growth factor receptor
  • Scientific Description
    The family of Trk receptor tyrosine kinases consists of TrkA, TrkB, and TrkC. While the sequence of these family members is highly conserved, they are activated by different neurotrophins: TrkA by NGF, TrkB by BDNF or NT4, and TrkC by NT3. In the adult nervous system, the Trk receptors regulate synaptic strength and plasticity. TrkA regulates proliferation and is important for development and maturation of the nervous system. Point mutations, deletions, and chromosomal rearrangements (chimeras) cause ligand-independent receptor dimerization and activation of TrkA. TrkA is activated in many malignancies including breast, ovarian, prostate, and thyroid carcinomas. TrkB is overexpressed in tumors such as neuroblastoma, prostate adenocarcinoma and pancreatic ductal adenocarcinoma. In neuroblastomas overexpression of TrkB correlates with unfavorable disease outcome when autocrine loops signaling tumor survival are potentiated by additional overexpression of brain-derived neurotrophic factor (BDNF). An alternatively spliced truncated TrkB isoform lacking the kinase domain is overexpressed in Wilms tumors and this isoform may act as a dominant-negative to TrkB signaling. Altered TrkC expression and corresponding gene mutations are seen in various forms of cancer, with increased expression a positive prognostic indicator in patients with medulloblastoma.
  • Reactivity
    Human, Mouse, Rat
  • Reactivity Supplier
    Human,Mouse,Rat
  • Storage Instruction
    -20°C,2°C to 8°C
  • UNSPSC
    41116161